Literature DB >> 16504607

Identification of bilirubin reduction products formed by Clostridium perfringens isolated from human neonatal fecal flora.

Libor Vítek1, Filip Majer, Lucie Muchová, Jaroslav Zelenka, Alena Jirásková, Pavel Branný, Jirí Malina, Karel Ubik.   

Abstract

Urobilinoids belong to the heterogenous group of degradation products of bilirubin formed in the gastrointestinal tract by intestinal microflora. Among them urobilinogen and stercobilinogen with their respective oxidation products, urobilin and stercobilin, are the most important compounds. The aim of present study was to analyze the products of bacterial reduction of bilirubin in more detail. The strain of Clostridium perfringens isolated from neonatal stools, capable of reducing bilirubin, was used in the study. Bacteria were incubated under anaerobic conditions with various native as well as synthetic bile pigments, including radiolabeled unconjugated bilirubin (UCB). Their reduction products were extracted from media and separated following thin layer chromatography. Pigments isolated were analyzed by spectrophotometry, spectrofluorometry and mass spectrometry. In a special set of experiments, bilirubin diglucuronide was incubated with either bacterial lysate or partially purified bilirubin reductase and beta-glucuronidase to reveal whether bilirubin glucuronides may be directly reduced onto conjugated urobilinoids. A broad substrate activity was detected in the investigated strain of C. perfringens and a series of bilirubin reduction products was identified. These products were separated in the form of their respective chromogens and further oxidized. Based on their physical-chemical properties, as well as mass spectra, end-catabolic bilirubin products were identified to belong to urobilinogen species. The reduction process, catalyzed enzymatically by the studied bacterial strain, does not proceed to stercobilinogen. Bilirubin diglucuronide is not reduced onto urobilinoid conjugates, glucuronide hydrolysis must precede double bond reduction and thus UCB is reduced much faster.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16504607     DOI: 10.1016/j.jchromb.2006.01.032

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  9 in total

1.  Prebiotics for the prevention of hyperbilirubinaemia in neonates.

Authors:  Amir Mohammad Armanian; Shayesteh Jahanfar; Awat Feizi; Nima Salehimehr; Mitra Molaeinezhad; Erfan Sadeghi
Journal:  Cochrane Database Syst Rev       Date:  2019-08-13

Review 2.  Bilirubin in the Liver-Gut Signaling Axis.

Authors:  Abdul-Rizaq Hamoud; Lauren Weaver; David E Stec; Terry D Hinds
Journal:  Trends Endocrinol Metab       Date:  2018-02-03       Impact factor: 12.015

3.  Bile pigment pharmacokinetics and absorption in the rat: therapeutic potential for enteral administration.

Authors:  A C Bulmer; J S Coombes; J T Blanchfield; I Toth; R G Fassett; S M Taylor
Journal:  Br J Pharmacol       Date:  2011-12       Impact factor: 8.739

4.  Depletion of Stercobilin in Fecal Matter from a Mouse Model of Autism Spectrum Disorders.

Authors:  Emily R Sekera; Heather L Rudolph; Stephen D Carro; Michael J Morales; Glenna C L Bett; Randall L Rasmusson; Troy D Wood
Journal:  Metabolomics       Date:  2017-10-03       Impact factor: 4.290

Review 5.  Bilirubin as a metabolic hormone: the physiological relevance of low levels.

Authors:  Justin F Creeden; Darren M Gordon; David E Stec; Terry D Hinds
Journal:  Am J Physiol Endocrinol Metab       Date:  2020-12-07       Impact factor: 4.310

Review 6.  Biological Effects of Indole-3-Propionic Acid, a Gut Microbiota-Derived Metabolite, and Its Precursor Tryptophan in Mammals' Health and Disease.

Authors:  Piotr Konopelski; Izabella Mogilnicka
Journal:  Int J Mol Sci       Date:  2022-01-22       Impact factor: 5.923

7.  Potential of therapeutic bile acids in the treatment of neonatal Hyperbilirubinemia.

Authors:  Lori W E van der Schoor; Henkjan J Verkade; Anna Bertolini; Sanne de Wit; Elvira Mennillo; Eva Rettenmeier; André A Weber; Rick Havinga; Petra Valášková; Jana Jašprová; Dicky Struik; Vincent W Bloks; Shujuan Chen; Andrea B Schreuder; Libor Vítek; Robert H Tukey; Johan W Jonker
Journal:  Sci Rep       Date:  2021-05-27       Impact factor: 4.379

8.  Mesobiliverdin IXα Enhances Rat Pancreatic Islet Yield and Function.

Authors:  Taihei Ito; Dong Chen; Cheng-Wei Tom Chang; Takashi Kenmochi; Tomonori Saito; Satoshi Suzuki; Jon Y Takemoto
Journal:  Front Pharmacol       Date:  2013-04-23       Impact factor: 5.810

9.  A product of heme catabolism modulates bacterial function and survival.

Authors:  Christopher L Nobles; Sabrina I Green; Anthony W Maresso
Journal:  PLoS Pathog       Date:  2013-07-25       Impact factor: 6.823

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.